In the past decade, weight loss tablets like Ozempic and Wegovy, initially prescribed for type 2 diabetes, have turned into hugely popular weight loss supplements. The drugs are part of a class called GLP-1 receptor agonists that reduce hunger, delay digestion, and improve the sensitivity to insulin.
Clinical trials have been outstanding: patients lose 15–22% of their weight, especially with more recent drugs like tirzepatide and retatrutide. In practice, however, studies show a less encouraging picture with mean weight loss at approximately 6–7%—basically due to poor compliance, side effects, and cost.
Side effects like nausea, vomiting, and fatigue are common. More serious are less common but dangerous illnesses like pancreatitis, gallbladder disease, and muscle wasting. Studies also show that most people regain the weight within a year of stopping the drug.
Despite all the frenzy, these medications are no magic bullet. They work best when coupled with lifestyle changes—and may need to be used for years to produce intended outcomes. There are also ethical concerns with limited access, high prices, and aggressive marketing overshadowing the science.
In short, GLP-1 medications are a useful tool—not a cure-all. Success depends on realistic expectations, clinician support, and equity in access.